12:00 AM
Jun 15, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Inhaled L-CsA: Phase Ib data

Data from 12 lung transplant patients in a German Phase Ib trial showed that inhaled L-CsA was well-tolerated and single 10 or 20 mg doses resulted in 40% and 33% lung deposition, respectively. This lung...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >